Related Experiment Video
Updated: Oct 2, 2025
08:52
Measurement of Protein Turnover Rates in Senescent and Non-Dividing Cultured Cells with Metabolic Labeling and Mass Spectrometry
Published on: April 6, 2022
3.7K
Aging, Cellular Senescence, and Alzheimer's Disease
1Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294-0006, USA.
International Journal of Molecular Sciences
|February 26, 2022
Summary
Cellular senescence, a hallmark of aging, contributes to late-onset Alzheimer's disease (LOAD). Removing senescent cells shows promise for treating aging-related diseases like Alzheimer's disease (AD).
Area of Science:
- Gerontology
- Neuroscience
- Cell Biology
Background:
- Aging is the primary risk factor for late-onset Alzheimer's disease (LOAD), accounting for over 95% of cases.
- Cellular senescence, a state of irreversible cell cycle arrest, is implicated in aging and age-related diseases, including Alzheimer's disease (AD).
- Senescent cells (astrocytes, microglia, endothelial cells, neurons) are present in the brains of AD patients and models.
Purpose of the Study:
- To review recent advances in understanding the role of cellular senescence in aging and AD.
- To explore the mechanisms driving cell senescence and its contribution to AD neuropathophysiology.
- To highlight senolytics as a potential therapeutic strategy for AD.
Main Methods:
- Review of current literature on cellular senescence, aging, and Alzheimer's disease.
- Analysis of studies detecting senescent cells in AD brains and models.
- Evaluation of research on the effects of senescent cell removal in AD models.
Main Results:
- Senescent cells are found in the brain in AD patients and animal models.
- Genetic or pharmacological removal of senescent cells improves neuropathology and memory in AD mouse models.
- Evidence suggests a critical role for cellular senescence in AD pathogenesis.
Conclusions:
- Cellular senescence is a significant factor in aging-related susceptibility to AD.
- Understanding the mechanisms of senescence in AD is crucial for developing effective treatments.
- Targeting and removing senescent cells offers a promising therapeutic avenue for AD and other aging-related diseases.
Keywords:
Alzheimer’s diseaseagingcellular senescencelate-onset Alzheimer’s disease (LOAD)neurodegenerationoxidative stressplasminogen activator inhibitor 1 (PAI-1)tauopathytelomere shorteningβ-amyloid peptides (Aβ)More Related Videos
06:23Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons
Published on: October 30, 2018
8.1K
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
10.4K
Related Concept Videos
01:26Aging
246
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
246
01:26Alzheimer's Disease: Overview
713
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
713
01:19The Effect of Aging on Tissues
2.8K
Several body functions deteriorate with age. The external signs of aging are easily identifiable. For example, the skin becomes dry, less elastic, and thins out, forming wrinkles. The skin of the face begins to appear looser due to a decrease in the levels of elastic and collagen fibers in the connective tissue. Additionally, melanin production in the hair follicle decreases with age, resulting in gray hair. Moreover, the senses of sight and hearing decline, so glasses and hearing aids may...
2.8K
01:37Mitochondria
15.4K
Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...
15.4K
01:22Alzheimer's Disease: Treatment
279
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
279
03:03Amyloid Fibrils
10.4K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
10.4K